title: In vivo targeting of intratumor regulatory T cells using PEG-modified single-walled carbon nanotubes.
abstract: Recent evidence regarding the role of regulatory T cells (Treg) in tumor development has suggested that the manipulation of Treg function selectively in the tumor microenvironment would be a desirable immunotherapy approach. Targeting intratumor immune populations would reduce side effects on peripheral healthy cells and increase antitumor efficacy of immunotherapies. However, no current approaches are available which enable selective in vivo targeting of intratumor Treg or other immune cell subpopulations. Herein, we investigated the ability of ligands against Treg-specific receptors to drive selective internalization of PEG-modified single-walled carbon nanotubes (PEG-SWCNTs) into Treg residing in the tumor microenvironment. We focused our attention on the glucocorticoid-induced TNFR-related receptor (GITR), as it showed higher overexpression on intratumor vs peripheral (i.e., splenic) Treg compared to other reported Treg-specific markers (folate receptor 4, CD103, and CD39). Ex vivo investigations showed that the Treg targeting efficiency and selectivity of PEG-SWCNTs depended on incubation time, dose, number of ligands per nanotube, and targeted surface marker. In vivo investigations showed that PEG-SWCNTs armed with GITR ligands targeted Treg residing in a B16 melanoma more efficiently then intratumor non-Treg or splenic Treg. The latter result was achieved by exploiting a combination of passive tumor targeting due to enhanced tumor vascular permeability, naturally increased intratumor Treg vs effector T cell (Teff) ratio, and active targeting of markers that are enriched in intratumor vs splenic Treg. We also found that PEG-SWCNTs loaded with GITR ligands were internalized by Treg through receptor-mediated endocytosis and transported into the cytoplasm and nucleus ex vivo and in vivo. This is the first example of intratumor immune cell targeting and we hope it will pave the way to innovative immunotherapies against cancer.
authors.affiliation: Inflammatory and Infectious Disease Center, Sanford Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, California 92037, United States.
authors.forename: Cristiano
authors.initials: C
authors.lastname: Sacchetti
authors.forename: Novella
authors.initials: N
authors.lastname: Rapini
authors.forename: Andrea
authors.initials: A
authors.lastname: Magrini
authors.forename: Elisa
authors.initials: E
authors.lastname: Cirelli
authors.forename: Stefano
authors.initials: S
authors.lastname: Bellucci
authors.forename: Maurizio
authors.initials: M
authors.lastname: Mattei
authors.forename: Nicola
authors.initials: N
authors.lastname: Rosato
authors.forename: Nunzio
authors.initials: N
authors.lastname: Bottini
authors.forename: Massimo
authors.initials: M
authors.lastname: Bottini
mesh_terms: D000818:Animals; D004305:Dose-Response Relationship, Drug; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D037742:Nanotubes, Carbon / Q000737:chemistry*; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000276:immunology*; D011092:Polyethylene Glycols / Q000737:chemistry / Q000494:pharmacology*; D011948:Receptors, Antigen, T-Cell / Q000037:antagonists & inhibitors / Q000276:immunology; D013329:Structure-Activity Relationship; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects* / Q000276:immunology*; D023041:Xenograft Model Antitumor Assays
chemical_list: D037742:Nanotubes, Carbon; D011948:Receptors, Antigen, T-Cell; D011092:Polyethylene Glycols